{
    "clinical_study": {
        "@rank": "163081", 
        "arm_group": [
            {
                "arm_group_label": "Loteprednol", 
                "arm_group_type": "Active Comparator", 
                "description": "Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months"
            }, 
            {
                "arm_group_label": "Prednisolone acetate", 
                "arm_group_type": "Active Comparator", 
                "description": "Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Graft rejection has traditionally been one of the leading causes of cornea transplant\n      failure. To help prevent rejection, corticosteroid eye drops are used for an extended period\n      after transplant surgery. The purpose of this study is to compare the efficacy and side\n      effects of different corticosteroid dosing regimens after endothelial keratoplasty (cornea\n      transplant) surgery."
        }, 
        "brief_title": "Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Fuchs' Dystrophy", 
            "Corneal Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Corneal Edema", 
                "Edema", 
                "Fuchs' Endothelial Dystrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Male or female patient who had endothelial keratoplasty procedure within the past 1\n             to 7 weeks\n\n          -  Patient is able and willing to administer eye drops\n\n          -  Patient is able to comprehend and has signed the Informed Consent form.\n\n          -  Patient is likely to complete the one-year course of the study\n\n        Exclusion Criteria:\n\n          -  A history of a previous rejection episode in the study eye\n\n          -  A patient exhibiting intraocular inflammation\n\n          -  A patient with a known sensitivity to any of the ingredients in the study medications\n\n          -  A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a\n             situation which in the investigator's opinion may put the patient at significant\n             risk, may confound the study results, or may interfere significantly with the\n             patient's participation in the study\n\n          -  A patient with abnormal eyelid function.\n\n          -  A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis,\n             or who has a history of herpetic keratitis.\n\n          -  Presence of any ocular disease that would interfere with the evaluation of the study\n             treatment.  However, patients with a history of cystoid macular edema, age-related\n             macular degeneration, controlled glaucoma, corneal neovascularization, and other\n             non-interfering comorbidities may be enrolled.\n\n          -  A patient with a history of non-compliance with using prescribed medication.\n\n          -  A patient who is concurrently involved in or participated in another randomized\n             clinical trial within 30 days prior to enrollment in this study.\n\n          -  Patients who are pregnant or planning to become pregnant within the duration of the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853696", 
            "org_study_id": "2013-0424"
        }, 
        "intervention": [
            {
                "arm_group_label": "Loteprednol", 
                "intervention_name": "loteprednol etabonate", 
                "intervention_type": "Drug", 
                "other_name": "Lotemax gel"
            }, 
            {
                "arm_group_label": "Prednisolone acetate", 
                "intervention_name": "prednisolone acetate 1%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Loteprednol etabonate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46260"
                }, 
                "name": "Price Vision Group"
            }, 
            "investigator": {
                "last_name": "Francis W Price, Jr, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty", 
        "overall_contact": {
            "email": "mprice@cornea.org", 
            "last_name": "Marianne Price, PhD", 
            "phone": "317-814-2990"
        }, 
        "overall_official": {
            "affiliation": "Price Vision Group", 
            "last_name": "Francis W Price, Jr., MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline intraocular pressure", 
            "safety_issue": "Yes", 
            "time_frame": "1, 3, 6 and 12 months after transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853696"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Immunologic graft rejection episode", 
            "safety_issue": "Yes", 
            "time_frame": "within first year after cornea transplantation"
        }, 
        "source": "Cornea Research Foundation of America", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cornea Research Foundation of America", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}